Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

LLM 2021 | Mechanism of action of belantamab mafodotin

James Berenson • 12 Oct 2021
LLM 2021
Multiple Myeloma Antibodies Belantamab mafodotin

James Berenson, MD, Institute for Myeloma and Bone Cancer Research, West Hollywood, CA, outlines the mechanism of action of belantamab mafodotin, an anti-B cell maturation antigen (BCMA) antibody-drug conjugate indicated for relapsed/refractory multiple myeloma. Belantamab selectively binds to BCMA and the conjugated monomethyl auristatin F (MMAF) mediates myeloma cell death. This interview took place at the Lymphoma, Leukemia & Myeloma Congress 2021.

Disclosures

Speaker’s Bureau, Consulting, and Research Grant Support: BMS, Takeda Oncology, Karyopharm, Oncopeptides, and AMGEN
Speaker’s Bureau: Janssen and AMAG
Major Stockholder: ONCOtracker

More from James Berenson

The addition of isatuximab to KRd improves transplant outcomes for patients with multiple myeloma 1:16
The addition of isatuximab to KRd improves transplant outcomes for patients with multiple myeloma
James Berenson • 14 Dec 2023
Medical writing bias in myeloma clinical research 1:09
Medical writing bias in myeloma clinical research
James Berenson • 11 Dec 2023
Addition of lenalidomide to patients with myeloma progressing on ruxolitinib and methylprednisolone 2:07
Addition of lenalidomide to patients with myeloma progressing on ruxolitinib and methylprednisolone
James Berenson • 11 Dec 2023
Outcomes of patients with triple-class refractory myeloma: a single-center retrospective study 1:08
Outcomes of patients with triple-class refractory myeloma: a single-center retrospective study
James Berenson • 11 Dec 2023

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals